Current Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
|
|
- Elvin Haynes
- 5 years ago
- Views:
Transcription
1 Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
2 Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours Remote onset 2 months ago Palpitation persisted for 1~2 hours HTN (-), DM (-)
3
4 Echocardiography LVEF 67% LVESD/EDD 30/53 mm LA 42 mm LAVI 22 ml/m2 IVSd 10 mm, LVPWd 10 mm Normal LV and RV Valve : normal Great vessel : normal
5 What treatment strategy would you choose? 1. Rate control strategy 2. Rate control strategy with anticoagulation 3. Rhythm control strategy 4. Rhythm control strategy with anticoagulation 5. Anticoagulation only
6 Classification First detected AF Paroxysmal AF (Self- terminating) 7 days (most <24hr) Persistent AF (Not self- terminating) > 7 days Permanent AF (irreversible) Recurrent : two or more episode Longstanding persistent AF: continuous AF of greater than one-year duration
7 Diseases associated with AF Valvular Heart Disease : Rheumatic mitral disease Non-valvular HD : CAD, HTN Hyperthyroidism Pulmonary thromboembolism
8 Rhythm control for AF Pharmacologic treatment DC cardioversion RFCA (radiofrequency catheter ablation) Maze operation
9 Vaughan Williams Classification of Antiarrhythmic Drug Actions Type IA (block the sodium channel with intermediate recovery time) Disopyramide, Procainamide, Quinidine Type IB (block the sodium channel with rapid recovery time) Lidocaine, Mexiletine Type IC (block the sodium channel with slow recovery time) Flecainide, Moricizine, Propafenone Type II Beta-blockers (e.g., propranolol) Type III (prolongation of the cardiac action potential) Amiodarone, Bretylium, Dofetilide, Ibutilide, Sotalol Type IV Calcium-channel antagonists (e.g., verapamil and diltiazem)
10 Rhythm Control in AF 2014 AHA/ACC/HRS AF guideline
11
12 After Medication of Propafenone 300 mg bid
13 Atrial Fibrillation The most common cardiac arrhythmia. Confers a 5-fold risk of stroke. The rate of ischemic stroke among patients with AF averages 5% per year. One of five (20%) of all strokes is attributed to AF. The risk of death from AF-related stroke is doubled.
14 Treatment strategy of AF Prevention of thromboembolism : Antithrombotic therapy Rhythm control Rate control
15 Prevention of thromboembolism in AF patients Anticoagulant Anti-platelet agents Vitamin K Antagonist Aspirin +/- Clopidogrel Warfarin NOAC
16 Stroke prevention by Warfarin vs Aspirin in AF patients Stroke prevention 39% Hart RG et al, Ann Intern Med 1999;131:492
17 Stroke and ICH by INR in AF patients Hylek EM et al, N Engl J Med 1996;335:540 INR
18 CHA 2 DS 2 VASc score and stroke rate Risk factors CHF (1) HT (1) 75 yrs old (2) DM (1) Previous stroke, TIA, Thromboembolism (2) Vascular disease (1) 65~74 yrs old (1) Annual stroke rate Female (1) Camm AJ, et al. Eur Heart J 2010
19 HAS-BLED bleeding risk score Pisters R, et al, Chest 2010 Bleeding risk score Hypertension (1) Abnormal renal function (1) Abnormal liver function (1) Stroke (1) Bleeding (1) Labile INRs (1) Elderly > 65 yrs old (1) Drugs (1) Alcohol (1) Hypertension: systolic blood pressure >160 mmhg Abnormal kidney function: the presence of chronic dialysis or renal transplantation or serum creatinine 200 mol/l. Abnormal liver function: chronic hepatic disease (e.g. cirrhosis) or bilirubin >2 x upper limit of normal in association with aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase >3 x upper limit normal). Bleeding : previous bleeding history and/or predisposition to bleeding, e.g. bleeding diathesis, anemia, etc. Labile INRs : unstable/high INRs or poor time in therapeutic range (e.g. <60%) Drugs/alcohol use : concomitant use of drugs, such as antiplatelet agents, non-steroidal anti-inflammatory drugs, or alcohol abuse
20 CHA 2 DS 2 VASc score vs HAS-BLED score Stroke risk factors 75 yrs old (2) Previous stroke, TIA, Thromboembolism (2) CHF (1) HTN (1) DM (1) Vascular disease (1) 65~74 yrs old (1) Female (1) Bleeding risk score Elderly > 65 yrs old (1) Stroke (1) Hypertension (1) Abnormal renal function (1) Abnormal liver function (1) Bleeding (1) Labile INRs (1) Drugs (1) Alcohol (1)
21 Recommendations for Prevention of Thromboembolism in AF AHA/HRS 2014 OAC OAC/aspirin/No Tx No Tx
22 Case 1 CHA 2 DS 2 VASc score : 1 0 Female (1) ; lone AF HAS-BLED score : 0
23 What treatment strategy would you choose? 1. Rate control strategy 2. Rate control strategy with anticoagulation 3. Rhythm control strategy 4. Rhythm control strategy with anticoagulation 5. Anticoagulation only
24 Case 2 60 year-old gentleman Palpitation with chest discomfort, dizziness Drug refractory recurrent paroxysmal to persistent AF Medication Hx : propafenone, flecainide, sotalol Hypertension (+) with medication for 2 years
25
26 Echocardiography Normal LV cavity size & systolic function Normal LV wall thickness No regional wall motion abnormality LVEF: 68% LVIDs/LVIDd: 27/48mm LA: 40mm LAVI: 25.7ml/m2 IVSd : 9mm LVPWd: 10mm E: 0.89m/s e`: 0.164m/s E/e`: 5.43 Ao: 27mm DT: 119.0msec
27 CHA 2 DS 2 VASc score : 1 HTN HAS-BLED score : 1 HTN
28 What treatment strategy would you choose? 1. Rate control strategy 2. Rate control strategy with anticoagulation 3. Rhythm control strategy 4. Rhythm control strategy with anticoagulation 5. Anticoagulation only
29 A conceptual model of atrial fibrillation events in relationship to underlying substrate. Both primary disease and AF-induced structural, electrical, and autonomic remodelling contribute to progression from paroxysmal to persistent AF. Nattel S, et al. Eur Heart J 2014
30 Recommendations for Thromboembolism Prevention in Cardioversion of AF/AFL Recommendations COR LOE With AF or atrial flutter for 48 h, or unknown duration, anticoagulate with warfarin for at least 3 weeks prior to and 4 weeks after cardioversion With AF or atrial flutter for 48 h or unknown duration and no anticoagulation for preceding 3 weeks, it is reasonable to perform a TEE prior to cardioversion, and then cardiovert if no LA thrombus is identified, provided anticoagulation is achieved before TEE and maintained after cardioversion for at least 4 weeks With AF or atrial flutter 48 h, or unknown duration, anticoagulation with dabigatran, rivaroxaban, or apixaban is reasonable for 3 weeks prior to and 4 weeks after cardioversion I IIa IIa B B C 2014 AHA/ACC/HRS AF guideline
31 Recurrence of Atrial Fibrillation patients after DC cardioversion
32 What treatment strategy would you choose? 1. Rate control strategy 2. Rate control strategy with anticoagulation 3. Rhythm control strategy 4. Rhythm control strategy with anticoagulation 5. Anticoagulation only
33 Recommendations for Rate Control in AF Recommendations COR LOE Control ventricular rate using a beta blocker or nondihydropyridine calcium channel antagonist for paroxysmal, persistent, or permanent AF A heart rate control (resting heart rate <80 bpm) strategy is reasonable for symptomatic management of AF AV nodal ablation with permanent ventricular pacing is reasonable when pharmacological management is inadequate and rhythm control is not achievable Lenient rate control strategy (resting heart rate <110 bpm) may be reasonable with asymptomatic patients and LV systolic function is preserved I IIa IIa IIb B B B B
34 Radiofrequency Catheter Ablation (RFCA) Radiofrequency lesion in human ventricular myocardium
35 Initiation of Atrial Fibrillation by LSPV ectopic
36
37 PAC & induction of AF
38 PV Isolation by Catheter Ablation AF ablation : to eliminate AF triggers to modify the susceptible substrates
39 Three dimensional map of the LA and PV Radiofrequency lesions CT angiography
40
41 Indications for catheter ablation of AF Indications for catheter ablation of AF Class Level Symptomatic AF refractory or intolerant to at least one Class 1 or 3 antiarrhythmic medication Paroxysmal : Catheter ablation is recommended Persistent : Catheter ablation is reasonable Longstanding Persistent (>12 months) : Catheter ablation may be considered Symptomatic AF prior to initiation of antiarrhythmic drug therapy with a Class 1 or 3 antiarrhythmic agent I IIa IIb A A B Paroxysmal : Catheter ablation is reasonable Persistent : Catheter ablation may be considered Longstanding Persistent : Catheter ablation may be considered IIa IIb IIb B C C 2014 AHA/ACC/HRS AF guideline
42 Korea Reimbursement criteria for AF catheter ablation by Health Insurance Review and Assessment Service 심방세동고주파절제술의보험급여기준 가. 항부정맥약제 (I or III) 중 1 가지이상을 6 주이상충분한용량으로투여한이후에도증상이조절되지않는심방세동, 약제투여전, 후심전도검사에서심방세동이증명된경우 영구형 (permanent) 심방세동에는인정하지않음 나. 항부정맥약제에대한부작용또는동결절기능부전을동반한빈맥 - 서맥증후군에서와같이약제유지가불가능한심방세동으로심전도에서확인된경우 다. 재시술은이전시술후 3 개월이경과된이후에실시, 심전도상심방세동또는심방빈맥의재발이증명된경우 보험인정기준
43 Case 3 68 year-old gentleman Frequent dizziness with palpitation No functional decline Hypertension (+), DM (+) Medication of HTN and DM
44 Tachycardia Bradycardia syndrome 1 초
45 CHA 2 DS 2 VASc score : 3 Age 68 yrs HTN DM HAS-BLED score : 2 Age 68 yrs HTN
46 What treatment strategy would you choose? 1. Rate control strategy with anticoagulation 2. Rhythm control strategy 3. Rhythm control strategy with anticoagulation 4. Anticoagulation only 5. Pacemaker
47 Points to be considered 1. Tachycardia-bradycardia? 2. Underlying Sick sinus syndrome?
48 What treatment strategy would you choose? 1. Rate control strategy with anticoagulation 2. Rhythm control strategy 3. Rhythm control strategy with anticoagulation 4. Anticoagulation only 5. Pacemaker
49 Case 4 65 year-old lady No specific symptom Detection of AF in ECG during routine health check up No functional decline Medication of beta blocker No underlying heart and other problem
50
51 Echocardiography LVEF 58% LVESD/EDD 33/51 mm LA 58 mm LAVI 45 ml/m2 IVSd 10 mm, LVPWd 10 mm Normal LV and RV Valve : normal Great vessel : normal
52 What treatment strategy would you choose? 1. Rate control strategy 2. Rate control strategy with anticoagulation 3. Rhythm control strategy 4. Rhythm control strategy with anticoagulation 5. Anticoagulation only
53 Case 4 CHA 2 DS 2 VASc score : 2 65 years old (1) Female (1) HAS-BLED score : 1 65 years old (1)
54 Not an ideal candidate for AF ablation : The patient has a more advanced form of AF. There is little to be gained from a symptom perspective AF ablation should not be performed for solely curative purposes. The predominant arrhythmia mechanism shifts from a focal trigger in paroxysmal AF, to a reliance on an abnormal anatomic substrate capable of arrhythmia self-perpetuation.
55 What treatment strategy would you choose? 1. Rate control strategy 2. Rate control strategy with anticoagulation 3. Rhythm control strategy 4. Rhythm control strategy with anticoagulation 5. Anticoagulation only
56 Summary The rate of ischemic stroke among patients with AF averages 5% per year. CHA2DS2-VASc score recommended to assess stroke risk. With prior stroke, TIA, or CHA2DS2-VASc score 2, oral anticoagulants recommended. Warfarin or NOAC With nonvalvular AF and CHA2DS2-VASc score of 0, it is reasonable to omit antithrombotic therapy. With AF or atrial flutter for 48 h, or unknown duration, anticoagulate with warfarin for at least 3 weeks prior to and 4 weeks after cardioversion. Catheter ablation of AF : symptomatic AF refractory or intolerant to antiarrhythmic medication
Basics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationPractical Rate and Rhythm Management of Atrial Fibrillation
Practical Rate and Rhythm Management of Atrial Fibrillation pocket guide UPDATED FEBRUARY 2013 Adapted from the ACCF/AHA/HRS 2011 Focused Updates Incorporated into the ACC/AHA/ESC Guidelines for the Management
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More information3/25/2017. Program Outline. Classification of Atrial Fibrillation
Alternate Strategies to Antiarrhythmic Therapy: The Role of Ablation Jennifer El Aile, MS, AGPCNP-BC Electrophysiology Nurse Practitioner Clinical Lecturer at the University of Michigan Program Outline
More informationΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ. ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C
ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΗΛΕΚΤΡΙΚΗ ΑΝΑΤΑΞΗ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ Καρδιολόγος, Ε/Α, Γ.Ν.Κατερίνης. F.E.S.C Definitions of AF: A Simplified Scheme Term Definition Paroxysmal AF AF that terminates
More informationDysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics
Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationRhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014
Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014 Financial disclosures Consultant Medtronic 3 reasons to evaluate and treat arrhythmias
More informationAF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT
AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT 5-2014 Atrial Fibrillation therapeutic Approach Rhythm Control Thromboembolism Prevention: Recommendations Direct-Current
More informationAtrial Fibrillation Cases. Dr Paul Broadhurst Consultant Cardiologist
Atrial Fibrillation Cases Dr Paul Broadhurst Consultant Cardiologist November 2011 Mr TH age 72 Routine medical for hypertension check Denies any symptoms despite close questioning PMH: hypertension, MI,
More informationTreatment strategy decision tree
strategy decision tree strategy decision tree Confirmed diagnosis of AF Further investigations and clinical assessment including risk stratification for stroke/thromboembolism Paroxysmal AF Persistent
More informationAnti arrhythmic drugs. Hilal Al Saffar College of medicine Baghdad University
Anti arrhythmic drugs Hilal Al Saffar College of medicine Baghdad University Mechanism of Arrhythmia Abnormal heart pulse formation Abnormal heart pulse conduction Classification of Arrhythmia Abnormal
More informationACTIVITY DISCLAIMER DISCLOSURE. Craig Barstow, MD, FAAFP. Learning Objectives. Associated Session(s) Arrhythmias and Dysrhythmias: PBL
ACTIVITY DISCLAIMER Arrhythmias and Dysrhythmias: PBL Craig Barstow, MD, FAAFP The material presented here is being made available by the American Academy of Family Physicians for educational purposes
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationFibs and Flutters: The Heart of the Matter
Fibs and Flutters: The Heart of the Matter Anita Ralstin, CNP By the Numbers Atrial Fibrillation Hospital Discharges /quarter for 2012 -- 116,500 Average Length of Stay 4 days Projected that 20% of those
More informationAtrial Fibrillation: It s More than a Rhythm
Atrial Fibrillation: It s More than a Rhythm Relax and Learn at the Farm 2013 DNP, RN, CCNS, CCRN-CMC, CHFN Cardiovascular Nursing Education Associates 1 The Quality of a Person s Life is Directly Proportional
More informationManuel Castella MD PhD Hospital Clínic, University of
Manuel Castella MD PhD Hospital Clínic, University of Barcelona mcaste@clinic.ub.es @mcastellamd www.escardio.org/guidelines European Heart Journal - doi:10.1093/eurheartj/ehw210 Providing integrated care
More informationHalf Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital
Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should
More information12 월 1 일 EP conference
12 월 1 일 EP conference Classification ( ACC/AHA/ESC ) Paroxysmal : start and stop by themselves, lasting less than 24hrs sometimes lasting up to 7days Persistent : lasting more than 7 days or that requre
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationOut with the old, in with The 2010 Atrial Fibrillation Guidelines
Out with the old, in with The 2010 Atrial Fibrillation Guidelines Kseniya Chernushkin B.Sc.(Pharm.), VCH/PHC Pharmacy Resident Mary Elliot B.Sc.(Pharm.), VCH/PHC Pharmacy Resident March 22, 2011 Outline
More informationManagement of Acute Atrial Fibrillation
Management of Acute Atrial Fibrillation Tanner Moser, PharmD PGY- Internal Medicine Pharmacy Resident May, 08 Objectives: Pharmacists Explain the epidemiology, pathophysiology, and risks associated with
More informationAtrial fibrillation: current approaches to management
DRUG REVIEW n Atrial fibrillation: current approaches to management Upasana Tayal MA, MRCP and Robert Greenbaum BSc, MD, FRCP, FESC, FACC Atrial fibrillation is the commonest arrhythmia and GPs have an
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More informationObjectives for Technicians. Objectives for Pharmacists. Pathophysiology. Conflict of Interest. Atrial Fibrillation
Warfar IN or Warfar-OUT? And Other Updates in the Management of Atrial Fibrillation Kimberly Ackerbauer, PharmD, BCPS Clinical Pharmacy Specialist Rush University Medical Center Conflict of Interest I
More informationAtrial Fibrillation and Common Supraventricular Tachycardias. Sunil Kapur MD
Atrial Fibrillation and Common Supraventricular Tachycardias Sunil Kapur MD Cardiac Electrophysiology Brigham and Women s Hospital Instructor, Harvard Medical School No disclosures Cardiac Conduction:
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationAtrial Fibrillation Management in the ED. J Fisher May 2014"
Atrial Fibrillation Management in the ED J Fisher May 2014" A 48 yr old man presents with palpitations. He had a big night last night with old mates. ECG How will you manage him? Why important? Common
More informationAtrial Fibrillation in the Emergency Department
Atrial Fibrillation in the Emergency Department Disclosures Edward Jauch, MD MS Research support National Institutes of Health funding (multiple trials) Novo Nordisk (drug in kind) STOP-IT Study Genentech
More information:{ic0fp'16. Geriatric Medicine: Optimal Heart Health Amid Changing Guidelines. (and the Evidence for When to Stray) Kevin Overbeck, DO
:{ic0fp'16 ACOFP 53 rd Annual Convention & Scientific Seminars Geriatric Medicine: Optimal Heart Health Amid Changing Guidelines (and the Evidence for When to Stray) Kevin Overbeck, DO Optimal Heart Health
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationProfessor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham
New Guidelines for SPAF Professor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham Stroke prevention and atrial fibrillation Epidemiology of atrial fibrillation How common is it?
More informationInnovations in AF Management
Innovations in AF Management Barry Boilson MD PhD FRCPI boilson.barry@mayo.edu Disclosures Relevant None financial relationship(s) with industry None Off Label Usage None Overview Mechanisms of AF AF as
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationMedical management of AF: drugs for rate and rhythm control
Medical management of AF: drugs for rate and rhythm control Adel Khalifa Sultan Hamad, BMS, MD, FGHRS, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist Head of Electrophysiology
More informationStuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med
Stuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med None There s no reason to panic. While it is true that one of the crew members is ill, slightly. Absence of discrete P waves Chaotic
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationAtrial Fibrillation. CVD Clinical Development Coordinator
Atrial Fibrillation CVD Clinical Development Coordinator Atrial Fibrillation What it is and why it's important Case identification Heart rate control and onward referral Managing AF-Related Stroke risk
More informationAtrial Fibrillation Ablation: in Whom and How
Update on Consensus Statement on Management of Atrial Fibrillation: EHRA 2012 Atrial Fibrillation Ablation: in Whom and How Update of HRS/EHRA AF/ECAS Ablation Document 2012 Anne M Gillis MD FHRS Professor
More informationAntiarrhythmic Drugs
Antiarrhythmic Drugs DR ATIF ALQUBBANY A S S I S T A N T P R O F E S S O R O F M E D I C I N E / C A R D I O L O G Y C O N S U L T A N T C A R D I O L O G Y & I N T E R V E N T I O N A L E P A C H D /
More informationArrhythmia 341. Ahmad Hersi Professor of Cardiology KSU
Arrhythmia 341 Ahmad Hersi Professor of Cardiology KSU Objectives Epidemiology and Mechanisms of AF Evaluation of AF patients Classification of AF Treatment and Risk stratification of AF Identify other
More information4/25/2017. Atrial Fibrillation Review. John Evans, D.O. April 29 th, No disclosures
Atrial Fibrillation Review John Evans, D.O. April 29 th, 2017 No disclosures 1 Atrial Fibrillation Review: Learning Goals Stroke Prevention Rate Control Rhythm Control Drugs Ablation Cardioversion Atrial
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationStroke Prevention & Atrial Fibrillation. Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015
Stroke Prevention & Atrial Fibrillation Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015 Learning Outcomes What is Atrial Fibrillation? Why is Atrial Fibrillation important? What causes
More informationUse of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital
Use of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital Content i. Rhythm versus Rate control ii. Anti-arrhythmic for Rhythm Control iii. Anti-arrhythmic for Rate
More informationrequesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group
October 2015 Our Ref: FOI.15.ASH0149 requesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group Original Request Survey attached. Question 1: Between 1 July 2014 and
More informationPediatrics ECG Monitoring. Pediatric Intensive Care Unit Emergency Division
Pediatrics ECG Monitoring Pediatric Intensive Care Unit Emergency Division 1 Conditions Leading to Pediatric Cardiology Consultation 12.7% of annual consultation Is arrhythmias problems Geggel. Pediatrics.
More informationNew Concepts in the Management of Atrial Fibrillation
388 September 1999 New Concepts in the Management of Atrial Fibrillation L. LITTMANN Department of Internal Medicine, Carolinas Medical Center, Charlotte, North Carolina Summary This review summarizes
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationAtrial Fibrillation: Guidelines through clinical cases and 2010 updates
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology World incidence 720, 000 new cases / year World prevalence 5.5 million
More informationThe Age of the Novel Anticoagulants. Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology
The Age of the Novel Anticoagulants Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology Disclosures Speaker bureau for the Bristol-Myers Squibb and Pfizer alliance for Eliquis Direct
More information5/5/2010. World incidence 720, 000 new cases / year. World prevalence 5.55 million AF prevalence increasing with aging of population
Atrial Fibrillation: Guidelines through clinical cases and 2010 updates Samy Claude ELAYI Cardiac Clinical Pacing and Electrophysiology UK World incidence 720, 000 new cases / year World prevalence 5.55
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationHAS-BLED. Ron Pisters, MD Maastricht University Medical Centre (NL) No conflict of interest
HAS-BLED Ron Pisters, MD Maastricht University Medical Centre (NL) No conflict of interest r.pisters@mumc.nl Background major bleeding risk High stroke risk frequently warrants use of oral anticoagulation
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationArrhythmias (I) Supraventricular Tachycardias. Disclosures
Arrhythmias (I) Supraventricular Tachycardias Amy Leigh Miller, MD, PhD Cardiovascular Electrophysiology, Brigham & Women s Hospital Disclosures None Short R-P Tachycardia REGULAR with 1:1 P/R relationship
More informationAtrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency
Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation
More informationState of the Art Management on Atrial Fibrillation in Monica Lo, MD, FACC, FHRS April 15, 2016
State of the Art Management on Atrial Fibrillation in 2016 Monica Lo, MD, FACC, FHRS April 15, 2016 Scope of the Problem More than 30 million people worldwide 1 5 million new cases each year 1 in 4 lifetime
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A AADs. See Antiarrhythmic drugs (AADs) ACE inhibitors. See Angiotensin-converting enzyme (ACE) inhibitors ACP in transseptal approach to
More informationECGs and Arrhythmias: Family Medicine Board Review 2012
Overview ECGs and Arrhythmias: Family Medicine Board Review 2012 Jess Waldura, MD University of California, San Francisco walduraj@nccc.ucsf.edu Bundle branch blocks Quick review of ischemia Arrhythmias
More informationSupplementary Online Content
Supplementary Online Content Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): a randomzied clinical
More informationAblation Update and Case Studies. Lawrence Nair, MD, FACC Director of Electrophysiology Presbyterian Heart Group
Ablation Update and Case Studies Lawrence Nair, MD, FACC Director of Electrophysiology Presbyterian Heart Group Disclosures No financial relationships to disclose Objectives At the conclusion of this activity,
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationAtrial Fibrillation 10/2/2018. Depolarization & ECG. Atrial Fibrillation. Hemodynamic Consequences
Depolarization & ECG Atrial Fibrillation How to make ORDER out of CHAOS Julia Shih, VMD, DACVIM (Cardiology) October 27, 2018 Depolarization & ECG Depolarization & ECG Atrial Fibrillation Hemodynamic Consequences
More informationCanadian Cardiovascular Society Atrial Fibrillation Guidelines
Canadian Cardiovascular Society 2010 Atrial Fibrillation Guidelines Table of Contents Table of Contents... 2 Author Listing... 3 Chapter 2: Atrial Fibrillation: Etiology and Initial Investigations... 6
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationFred Kusumoto Professor of Medicine
Fred Kusumoto Professor of Medicine Faculty photo will be placed here Kusumoto.Fred@mayo.edu 2015 MFMER 3543652-1 Atrial Fibrillation Presentation Subtitle Here Mayo School of Continuous Professional Development
More informationConflicts of Interests
Advances in the Management of Atrial Fibrillation State of the Art in 2013 Overview of AF Stroke risk and anticoagulation Rate control Antiarrhythmic Drug Therapy Catheter ablation Conclusion Hugh Calkins
More informationManagement of Atrial Fibrillation in the Hospitalized Patient
Management of Atrial Fibrillation in the Hospitalized Patient Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research:
More informationLearn and LiveSM. ACC/AHA Pocket Guideline. Based on the ACC/AHA/ESC Guidelines for the. Management of Patients With. Atrial Fibrillation
Learn and LiveSM ACC/AHA Pocket Guideline Based on the ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation July 2007 Management of Patients With Atrial Fibrillation July 2007
More informationInitial Evaluation and Early Stabilization: Best Practices for the AF Patient Wayne Ruppert, CVT, CCCC, NREMT-P
Initial Evaluation and Early Stabilization: Best Practices for the AF Patient Wayne Ruppert, CVT, CCCC, NREMT-P Cardiovascular Coordinator Bayfront Health Dade City This presentation is available for download
More informationMANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017
MANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017 1 Faculty Disclosure Faculty: Peter Leong-Sit MSc, MD, FRCPC, FHRS Associate Professor, Western University Cardiologist, London Heart
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More informationLearning Objectives. Introduction 6/11/2018
Learning Objectives Chronic Non-Valvular Atrial Fibrillation & A Pharmacy-based Population Health Model for Detection of Atrial Fibrillation Joe R. Anderson, Pharm.D. PhC Barry E. Bleske, Pharm. D, FCCP
More informationקוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן
קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן INTRODUCTION The prevalence of atrial fibrillation (AF) is approximately 1.5 2% of the general population The arrhythmia is associated: with
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationMr. Eknath Kole M.S. Pharm (NIPER Mohali)
M.S. Pharm (NIPER Mohali) Drug Class Actions Therapeutic Uses Pharmacokinetics Adverse Effects Other Quinidine IA -Binds to open and inactivated Na+ -Decreases the slope of Phase 4 spontaneous depolarization
More informationReview Article. Korean Circulation Journal
Review Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal The Korean Heart Rhythm Society s 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation:
More information2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist
2015 Atrial Fibrillation Therapy Meds, Shock, or Ablate? D. Scott Kirby MD, FACC Cardiac Electrophysiologist Todays Objectives Atrial Fibrillation evaluation and treatment from an EP perspective Multimodal
More informationAtrial Fibrillation is Common. The (S)Low-down on Rapid Afib Resuscitation Step ED Dx - Rx 4/4/2017. There Are 5 Causes of Atrial Fibrillation
The (S)Low-down on Rapid Afib Resuscitation 2017 Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International Airport Nashville, TN Atrial Fibrillation
More informationAtrial fibrillation (AF) is the most common sustained. Management of Atrial Fibrillation CASE-BASED REVIEW
CASE-BASED REVIEW Management of Atrial Fibrillation Case Study and Commentary, Paul R. Sutton, MD, PhD, and Jane Y. Yeh, MD INSTRUCTIONS The following article, Management of Atrial Fibrillation, is a continuing
More informationDos and Don t in Cardiac Arrhythmia. Case 1 -ECG. Case 1. Management. Emergency Admissions. Reduction of TE risk -CHADS 2 score. Hospital Admissions
Emergency Admissions Dos and Don t in Cardiac Arrhythmia Tom Wong, MD, FESC Consultant Cardiologist, Honorary Senior Lecturer Royal Brompton & Harefield Hospitals National Heart and Lung Institute, Imperial
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationAtrial fibrillation and flutter in primary care
Atrial fibrillation and flutter in primary care Atrial fibrillation is underdiagnosed and undertreated Atrial fibrillation or flutter (AF)* occurs in approximately 1% of the general population. The prevalence
More informationAtrial fibrillation: Who should be referred for ablation therapy for atrial fibrillation?. September 12 th, 2015
Atrial fibrillation: Who should be referred for ablation therapy for atrial fibrillation?. September 12 th, 2015 MMMMMMM MMMMMMM MMMMMMM Sohail Hassan MD FACC, FHRS Director, Cardiac Electrophysiology
More information